Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration
Elizabeth J. Phillips, Simon A. Mallal
Elizabeth J. Phillips, Simon A. Mallal
Published May 21, 2018
Citation Information: J Clin Invest. 2018;128(7):2746-2749. https://doi.org/10.1172/JCI121525.
View: Text | PDF
Commentary

Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration

  • Text
  • PDF
Abstract

The discovery of HLA-B*57:01–associated abacavir hypersensitivity is a translational success story that eliminated adverse reactions to abacavir through pretreatment screening and defined a mechanistic model of an altered peptide repertoire. In this issue of the JCI, Cardone et al. have developed an HLA-B*57:01–transgenic mouse model and demonstrated that CD4+ T cells play a key role in mediating tolerance to the dramatically altered endogenous peptide repertoire induced by abacavir and postulate a known mechanism by which CD4+ T cells suppress DC maturation. This report potentially explains why 45% of HLA-B*57:01 carriers tolerate abacavir and provides a framework for future studies of HLA-restricted, T cell–mediated drug tolerance and hypersensitivity.

Authors

Elizabeth J. Phillips, Simon A. Mallal

×

Figure 1

Model of the mechanism of tolerance or hypersensitivity to abacavir in HLA-B*57:01–Tg mice.

Options: View larger image (or click on image) Download as PowerPoint
Model of the mechanism of tolerance or hypersensitivity to abacavir in H...
Model of the mechanism of tolerance or hypersensitivity to abacavir in HLA-B*57:01–Tg mice. Abacavir binds noncovalently to residues on the floor of the peptide-binding groove of the HLA-B*57:01 molecule and the overlying endogenous peptide, dramatically altering the repertoire of endogenous peptides presented to early-responding CD44hiCD62LhiCD8+ Tcm cells (see inset). CD4+ T cell depletion results in the maturation of DCs to a CD86hiCD80hiPD-L1hi phenotype that is capable of costimulation and induction of effector CD8+ T cells that can home to the skin and induce hypersensitivity. Without CD4+ T cell depletion, DCs remain in an immature state (CD86loCD80loPD-L1lo), and the mouse remains tolerant to the altered peptide repertoire. Tcm, T central memory cell; TCR, T cell receptor.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts